|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12345678910111213...4041» |
- ||| Trial completion, Trial completion date, Trial primary completion date: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - May 3, 2018
P=N/A, N=51, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018
- || Enrollment change: ALSCELL: Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study (clinicaltrials.gov) - May 1, 2018
P=N/A, N=19, Completed, Sponsor: Institut Pasteur
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018 N=30 --> 19
- | Phase classification, Trial termination: Gene Expression in MS Patients Before and During Treatment With Interferon-beta (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=600, Terminated, Sponsor: S. Andrea Hospital
N=30 --> 19 Phase classification: P4 --> P=N/A | Completed --> Terminated; Few participants enrolled
- | oxcarbazepine / Generic mfg.
Trial completion: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2018
P2a, N=30, Completed, Sponsor: Queen Mary University of London
Phase classification: P4 --> P=N/A | Completed --> Terminated; Few participants enrolled Recruiting --> Completed
- | Trial completion, Trial primary completion date: Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 17, 2018
P1/2, N=104, Completed, Sponsor: University of British Columbia
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2017
- | Enrollment change, Trial withdrawal: Progression of Cognitive and Physical Symptoms in Multiple Sclerosis (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Aug 2017 N=100 --> 0 | Enrolling by invitation --> Withdrawn
- | Trial completion: Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=101, Completed, Sponsor: Oregon Health and Science University
N=100 --> 0 | Enrolling by invitation --> Withdrawn Active, not recruiting --> Completed
- Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX (clinicaltrials.gov) - Apr 12, 2018
P4, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Active, not recruiting --> Completed N=20 --> 0
- | Trial completion: Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2018
P=N/A, N=67, Completed, Sponsor: National University of Natural Medicine
N=20 --> 0 Active, not recruiting --> Completed
- | Trial completion, Phase classification, Trial primary completion date: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Apr 9, 2018
P, N=148, Completed, Sponsor: McMaster University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial primary completion date: Dec 2016 --> Jun 2017
- || Betaseron (IFN-β-1b) / Bayer
Phase classification: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (clinicaltrials.gov) - Apr 6, 2018
P, N=1085, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial primary completion date: Dec 2016 --> Jun 2017 Phase classification: P=N/A --> P
- | Phase classification, Trial completion date, Trial primary completion date: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Apr 6, 2018
P, N=100, Recruiting, Sponsor: Claudio Gobbi
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- ||||||| Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
Trial completion, Trial completion date, Trial primary completion date: Efficacy and Safety of Circadin (clinicaltrials.gov) - Mar 30, 2018
P3, N=125, Completed, Sponsor: Neurim Pharmaceuticals Ltd.
Phase classification: P=N/A --> P | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Aug 2017 --> Mar 2018
- | Trial completion date, Trial primary completion date: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Mar 21, 2018
P=N/A, N=65, Recruiting, Sponsor: McGill University
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Aug 2017 --> Mar 2018 Trial completion date: Jun 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Sep 2018
- | Trial completion, Enrollment change: Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients. (clinicaltrials.gov) - Mar 12, 2018
P=N/A, N=10, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Trial completion date: Jun 2018 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Sep 2018 Recruiting --> Completed | N=30 --> 10
- | Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Rituximab in Systemic Sclerosis (clinicaltrials.gov) - Mar 2, 2018
P2/3, N=22, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed | N=30 --> 10 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2016
- | Myrbetriq (mirabegron) / Astellas
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - Feb 9, 2018
P2/3, N=32, Terminated, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Apr 2016 N=144 --> 32 | Enrolling by invitation --> Terminated | Trial primary completion date: Sep 2017 --> Jan 2018 | Trial completion date: Nov 2017 --> Feb 2018; Slow recruitment and small observed effect size
- | Catena (idebenone) / Chiesi
Trial primary completion date: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) - Feb 9, 2018
P1/2, N=85, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=144 --> 32 | Enrolling by invitation --> Terminated | Trial primary completion date: Sep 2017 --> Jan 2018 | Trial completion date: Nov 2017 --> Feb 2018; Slow recruitment and small observed effect size Trial primary completion date: Aug 2018 --> Apr 2018
- | imatinib / Generic mfg.
Trial completion, Trial primary completion date: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis (clinicaltrials.gov) - Feb 6, 2018
P2a, N=30, Completed, Sponsor: Hospital for Special Surgery, New York
Trial primary completion date: Aug 2018 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2011
- ||||||| everolimus / Generic mfg.
Trial completion, Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Feb 1, 2018
P3, N=370, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2011 Active, not recruiting --> Completed | Trial primary completion date: Oct 2017 --> Oct 2015
- | Catena (idebenone) / Chiesi
Trial primary completion date: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) - Jan 31, 2018
P1/2, N=85, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2017 --> Oct 2015 Trial primary completion date: Jan 2018 --> Aug 2018
- ||| Trial completion, Enrollment change: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=124, Completed, Sponsor: University of Miami
Trial primary completion date: Jan 2018 --> Aug 2018 Recruiting --> Completed | N=158 --> 124
- | Campath (alemtuzumab) / Sanofi
Trial primary completion date: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis (clinicaltrials.gov) - Jan 25, 2018
P1/2, N=3, Recruiting, Sponsor: Children's Hospital Los Angeles
Recruiting --> Completed | N=158 --> 124 Trial primary completion date: Jan 2018 --> Jan 2020
- | propranolol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Jan 24, 2018
P2, N=2, Completed, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Jan 2018 --> Jan 2020 Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Apr 2017 --> Nov 2017
- | Trial primary completion date: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Jan 18, 2018
P=N/A, N=88, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Apr 2017 --> Nov 2017 Trial primary completion date: Oct 2017 --> Oct 2018
- | Enrollment change: Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=200, Completed, Sponsor: Fondazione Italiana Sclerosi Multipla
Trial primary completion date: Oct 2017 --> Oct 2018 N=2000 --> 200
- | Trial completion, Enrollment change: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Jan 16, 2018
P3, N=38, Completed, Sponsor: University Hospital, Bordeaux
N=2000 --> 200 Recruiting --> Completed | N=80 --> 38
- | Trial completion: Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients (clinicaltrials.gov) - Jan 11, 2018
P=N/A, N=108, Completed, Sponsor: American University of Beirut Medical Center
Recruiting --> Completed | N=80 --> 38 Active, not recruiting --> Completed
- | dalfampridine / Generic mfg.
Trial completion, Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jan 9, 2018
P2, N=24, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017
- | Biomarker, Trial primary completion date: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=40, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017 Trial primary completion date: Dec 2017 --> Dec 2016
- | Trial primary completion date: Interferon ß-1b Treatment by Cyclical Administration (clinicaltrials.gov) - Jan 8, 2018
P2/3, N=60, Completed, Sponsor: S. Andrea Hospital
Trial primary completion date: Dec 2017 --> Dec 2016 Trial primary completion date: Feb 2011 --> Aug 2010
- | Trial completion, Trial primary completion date: MS-CARE: Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (clinicaltrials.gov) - Dec 6, 2017
P=N/A, N=195, Completed, Sponsor: University of Washington
Trial primary completion date: Feb 2011 --> Aug 2010 Enrolling by invitation --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, Trial completion: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Dec 5, 2017
P1/2, N=21, Completed, Sponsor: Boston University
Enrolling by invitation --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017 Active, not recruiting --> Completed
- | Trial completion: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=30, Completed, Sponsor: University Hospital of Ferrara
Active, not recruiting --> Completed Recruiting --> Completed
- | Mustargen (mechlorethamine) / Recordati
Trial completion, Metastases: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 19, 2017
P3, N=854, Completed, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: SOD1: Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=30, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
- | Farydak (panobinostat) / Secura Bio
Trial completion: A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 14, 2017
P2, N=24, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Aug 2017 --> Aug 2018 Active, not recruiting --> Completed
- | Trial completion: Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=108, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed Recruiting --> Completed
- | aHSCT / University of Calgary
Trial termination: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=3, Terminated, Sponsor: University of Calgary
Recruiting --> Completed Active, not recruiting --> Terminated; recruitment failure
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Combination therapy: Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=10, Completed, Sponsor: MinYoung Kim, M.D.
Active, not recruiting --> Terminated; recruitment failure Recruiting --> Completed
- | Nerventra (laquinimod) / Active Biotech
Trial termination, Trial primary completion date: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (clinicaltrials.gov) - Oct 11, 2017
P2, N=209, Terminated, Sponsor: Teva Pharmaceutical Industries, Ltd.
Recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2017; Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.
- | Enrollment change, Trial withdrawal, Trial primary completion date: Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Oct 11, 2017
P=N/A, N=0, Withdrawn, Sponsor: Rambam Health Care Campus
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2017; Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose. N=20 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Dec 2010 --> Jul 2009
- | Trial completion: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 11, 2017
P1, N=20, Completed, Sponsor: Tisch Multiple Sclerosis Research Center of New York
N=20 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Dec 2010 --> Jul 2009 Active, not recruiting --> Completed
- ||||| everolimus / Generic mfg.
Enrollment closed: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Oct 6, 2017
P3, N=370, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=15, Suspended, Sponsor: Stanford University
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- || fingolimod / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: McGill University
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A | N=400 --> 100 | Trial primary completion date: Nov 2019 --> Nov 2017
- | dronabinol oral / Generic mfg.
Trial initiation date, Trial primary completion date: Cannabis for Spasticity in Multiple Sclerosis (clinicaltrials.gov) - Sep 26, 2017
P1/2, N=42, Terminated, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A | N=400 --> 100 | Trial primary completion date: Nov 2019 --> Nov 2017 Initiation date: Mar 2003 --> Nov 2003 | Trial primary completion date: Jul 2017 --> Feb 2015
- | Trial primary completion date: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Sep 20, 2017
P=N/A, N=65, Recruiting, Sponsor: McGill University
Initiation date: Mar 2003 --> Nov 2003 | Trial primary completion date: Jul 2017 --> Feb 2015 Trial primary completion date: Apr 2017 --> Dec 2017
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Phase classification: Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases (clinicaltrials.gov) - Sep 20, 2017
P4, N=19, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Apr 2017 --> Dec 2017 Phase classification: P=N/A --> P4
- | Phase classification, Enrollment change: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=218, Active, not recruiting, Sponsor: VA Office of Research and Development
Phase classification: P=N/A --> P4 Phase classification: P3 --> P=N/A | N=600 --> 218